PT  - JOURNAL ARTICLE
AU  - Lin Zhu
AU  - Karl Ploessl
AU  - Rong Zhou
AU  - David Mankoff
AU  - Hank F. Kung
TI  - Metabolic Imaging of Glutamine in Cancer
AID  - 10.2967/jnumed.116.182345
DP  - 2017 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 533--537
VI  - 58
IP  - 4
4099  - http://jnm.snmjournals.org/content/58/4/533.short
4100  - http://jnm.snmjournals.org/content/58/4/533.full
SO  - J Nucl Med2017 Apr 01; 58
AB  - Glucose and glutamine are the most abundant nutrients for producing energy and building blocks in normal and tumor cells. Increased glycolysis in tumors, the Warburg Effect, is the basis for 18F-FDG PET imaging. Cancer cells can also be genetically reprogrammed to use glutamine. 5-11C-(2S)-glutamine and 18F-(2S,4R)4-fluoroglutamine may be useful complementary tools to measure changes in tumor metabolism. In glioma patients, the tracer 18F-(2S,4R)4-fluoroglutamine showed tumor-to-background contrast different from that of 18F-FDG and differences in uptake in glioma patients with clinical progression of disease versus stable disease (tumor-to-brain ratio > 3.7 in clinically active glioma tumors, minimal or no specific uptake in clinically stable tumors). These preliminary results suggest that 18F-(2S,4R)4-fluoroglutamine PET may be a new tool for probing in vivo metabolism of glutamine in cancer patients and for guiding glutamine-targeted therapeutics. Further studies of uptake mechanism, and comparison of kinetics for 18F-(2S,4R)4-fluoroglutamine versus the 11C-labeled native glutamine, will be important and enlightening.